Regulators of nfat and/or store-operated calcium entry
AssigneeImmune Disease Institute, Inc.
InventorsAnjana Rao, Patrick Hogan, Sonia Sharma
Life of this patent
Estimating the term…
Abstract
Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involved in the calcineurin/NFAT axis.
Claims20
A method of modulating NFAT activity in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity a protein and/or the expression of a gene identified in Table 4.
A method of modulating store-operated Ca2+ entry into a cell, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity of a protein and/or the expression of a gene identified in Table 4.
A method of treating and/or preventing hyperactivity or inappropriate immune response in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity a candidate protein and/or the expression of a gene identified in Table 4, wherein the gene is not calcineurin, calmodulin, Stim1 (stromal interaction molecule 1), Stim2 (stromal interaction molecule 2), Orai1 (calcium release-activated calcium modulator 1), KCNN4 (potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4) or dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2).
Dependencies are inferred from the claim text.